Nrf2 silencing to inhibit proteolytic defense induced by hyperthermia in HT22 cells

Redox Biology

Volumn 8, Issue , 2016, Pages 323-332

  Bozaykut, Perinur ^a,b   Ozer, Nesrin Kartal ^a   Karademir, Betul ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Department of Medical Oncology   (Turkey)

Author keywords

Heat shock proteins; Hyperthermia; Nrf2; Proteasome

Indexed keywords

GLUTATHIONE TRANSFERASE ALPHA; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; MESSENGER RNA; PROTEASOME; PROTEASOME SUBUNIT BETA 5; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; NFE2L2 PROTEIN, HUMAN;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL LINE; CELL NUCLEUS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HT22 CELL LINE; HYPERTHERMIA; HYPERTHERMIC THERAPY; IMMUNOBLOTTING; MOUSE; NONHUMAN; NRF2 GENE; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; GENETICS; HEAT TOLERANCE; HIPPOCAMPUS; HUMAN; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; THERMOTHERAPY;

ANIMALS; CELL LINE; GENE SILENCING; HIPPOCAMPUS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYPERTHERMIA, INDUCED; MICE; NEOPLASMS; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; THERMOTOLERANCE;

EID: 84960091385     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.03.001     Document Type: Article

References (55)

1. Wust P., Hildebrandt B., Sreenivasa G., Rau B., Gellermann J., Riess H., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002, 3:487-497.
2. Falk M.H., Issels R.D. Hyperthermia in oncology. Int. J. Hyperth. 2001, 17:1-18.
3. Chichel A., Skowronek J., Kanikowski M. Thermal boost combined with interstitial brachytherapy in breast conserving therapy-assessment of early Toxicity. Rep. Pract. Oncol. Radiother. 2011, 16:87-94.
4. Gerner E.W., Schneider M.J. Induced thermal resistance in HeLa cells. Nature 1975, 256:500-502.
5. Liu F.F., Miller N., Levin W., Zanke B., Cooper B., Henry M., et al. The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int. J. Hyperth. 1996, 12:197-208.
6. Yokota S., Kitahara M., Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000, 60:2942-2948.
7. Bozaykut P., Ozer N.K., Karademir B. Regulation of protein turnover by heat shock proteins. Free Radic. Biol. Med. 2014, 77:195-209.
8. Bozaykut P., Sozen E., Kaga E., Ece A., Ozaltin E., Ek B., et al. The role of heat stress on the age related protein Carbonylation. J. Proteome 2013, 89:238-254.
9. Alexiou G.A., Karamoutsios A., Lallas G., Ragos V., Goussia A., Kyritsis A.P., et al. Expression of heat shock proteins in brain tumors. Turk. Neurosurg. 2014, 24:745-749.
10. Kaigorodova E.V., Bogatyuk M.V. Heat shock proteins as prognostic markers of cancer. Curr. Cancer Drug. Targets 2014, 14:713-726.
11. Drysdale M.J., Brough P.A., Massey A., Jensen M.R., Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr. Opin. Drug. Discov. Dev. 2006, 9:483-495.
12. Zaarur N., Gabai V.L., Porco J.A., Calderwood S., Sherman M.Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 2006, 66:1783-1791.
13. Calderwood S.K., Asea A. Targeting HSP70-induced thermotolerance for design of thermal sensitizers. Int. J. Hyperth. 2002, 18:597-608.
14. Catalgol B. Proteasome and cancer. Prog. Mol. Biol. Transl. Sci. 2012, 109:277-293.
15. Adams J., Palombella V.J., Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Investig. New Drugs 2000, 18:109-121.
16. Myung J., Kim K.B., Crews C.M. The ubiquitin-proteasome pathway and Proteasome inhibitors. Med. Res. Rev. 2001, 21:245-273.
17. Catalgol B., Wendt B., Grimm S., Breusing N., Ozer N.K., Grune T. Chromatin repair after oxidative stress: role of PARP-mediated Proteasome activation. Free Radic. Biol. Med. 2010, 48:673-680.
18. Catalgol B., Grune T. Protein pool maintenance during oxidative stress. Curr. Pharm. Des. 2009, 15:3043-3051.
19. Jung T., Hohn A., Catalgol B., Grune T. Age-related differences in oxidative protein-damage in young and senescent fibroblasts. Arch. Biochem Biophys. 2009, 483:127-135.
20. Takimoto C.H., Diggikar S. Heat shock protein and Proteasome targeting Agents. Hematol. Oncol. Clin. North Am. 2002, 16:1269-1285.
21. Grune T., Reinheckel T., Davies K.J. Degradation of oxidized proteins in mammalian cells. Faseb J. 1997, 11:526-534.
22. Niforou K., Cheimonidou C., Trougakos I.P. Molecular chaperones and Proteostasis regulation during redox imbalance. Redox Biol. 2014, 2:323-332.
23. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
24. Buss H., Chan T.P., Sluis K.B., Domigan N.M., Winterbourn C.C. Protein carbonyl measurement by a sensitive ELISA method. Free Radic. Biol. Med. 1997, 23:361-366.
25. Kotoglou P., Kalaitzakis A., Vezyraki P., Tzavaras T., Michalis L.K., Dantzer F., et al. Hsp70 Translocates to the nuclei and nucleoli, binds to XRCC1 and PARP-1, and protects HeLa cells from single-strand DNA breaks. Cell Stress Chaperones 2009, 14:391-406.
26. Grune T., Catalgol B., Licht A., Ermak G., Pickering A.M., Ngo J.K., et al. HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radic. Biol. Med. 2011, 51:1355-1364.
27. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
28. Chapple S.J., Siow R.C., Mann G.E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell Biol. 2012, 44:1315-1320.
29. Sykiotis G.P., Bohmann D. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci. Signal 2010, 3. re3.
30. Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L. The keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013, 1:45-49.
31. Bryan H.K., Olayanju A., Goldring C.E., Park B.K. The Nrf2 cell defence pathway: keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol. 2013, 85:705-717.
32. Catalgol B., Grune T. Turnover of oxidatively modified proteins: the usage of in vitro and metabolic labeling. Free Radic. Biol. Med. 2009, 46:8-13.
33. Joshi G., Sultana R., Tangpong J., Cole M.P., Clair D.K., Vore M., et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic. Res. 2005, 39:1147-1154.
34. Hensen S.M., Heldens L., van Enckevort C.M., van Genesen S.T., Pruijn G.J., Lubsen N.H. Activation of the antioxidant response in methionine deprived human cells results in an HSF1-independent increase in HSPA1A mRNA levels. Biochimie 2013, 95:1245-1251.
35. Grimberg K.B., Beskow A., Lundin D., Davis M.M., Young P. Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the drosophila 26S Proteasome. Mol. Cell Biol. 2011, 31:897-909.
36. Tsakiri E.N., Iliaki K.K., Hohn A., Grimm S., Papassideri I.S., Grune T., et al. Diet-derived advanced glycation end products or Lipofuscin disrupts Proteostasis and reduces life span in drosophila Melanogaster. Free Radic. Biol. Med. 2013, 65:1155-1163.
37. Cui X.B., Yu Z.Y., Wang W., Zheng Y.Q., Liu W., Li L.X. Co-inhibition of HSP70/HSP90 Synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy. Integr. Cancer Ther. 2012, 11:61-67.
38. Beere H.M. The stress of dying: the role of heat shock proteins in the regulation of apoptosis. J. Cell Sci. 2004, 117:2641-2651.
39. Ravagnan L., Gurbuxani S., Susin S.A., Maisse C., Daugas E., Zamzami N., et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat. Cell Biol. 2001, 3:839-843.
40. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell Mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
41. Rossi A., Ciafre S., Balsamo M., Pierimarchi P., Santoro M.G. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance Hyperthermochemotherapy efficacy in cervical cancer. Cancer Res. 2006, 66:7678-7685.
42. Workman P., de B.E. Putting the heat on cancer. Nat. Med. 2007, 13:1415-1417.
43. Li G.C., Li L.G., Liu Y.K., Mak J.Y., Chen L.L., Lee W.M. Thermal response of rat fibroblasts stably transfected with the human 70-kDa heat shock protein-encoding gene. Proc. Natl. Acad. Sci. USA 1991, 88:1681-1685.
44. Ciocca D.R., Fuqua S.A., Lock-Lim S., Toft D.O., Welch W.J., McGuire W.L. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992, 52:3648-3654.
45. Vargas-Roig L.M., Gago F.E., Tello O., Aznar J.C., Ciocca D.R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer 1998, 79:468-475.
46. Catalgol B., Ziaja I., Breusing N., Jung T., Hohn A., Alpertunga B., et al. The proteasome is an integral part of solar ultraviolet a radiation-induced gene expression. J. Biol. Chem. 2009, 284:30076-30086.
47. Shah S.A., Potter M.W., Callery M.P. Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg. Oncol. 2001, 10:43-52.
48. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 2004, 10:3839-3852.
49. Kim J., Guan J., Chang I., Chen X., Han D., Wang C.Y. PS-341 and histone Deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol. Cancer Ther. 2010, 9:1977-1984.
50. Kastle M., Woschee E., Grune T. Histone deacetylase 6 (HDAC6) plays a crucial role in p38MAPK-dependent induction of heme oxygenase-1 (HO-1) in response to proteasome inhibition. Free Radic. Biol. Med. 2012, 53:2092-2101.
51. Raaphorst G.P., Feeley M.M. Comparison of recovery from potentially lethal damage after exposure to hyperthermia and radiation. Radiat. Res. 1990, 121:107-110.
52. van der Zee J. Heating the patient: a promising approach?. Ann. Oncol. 2002, 13:1173-1184.
53. van der Zee J., De B.M., Mens J.W., Ameziane A., Broekmeyer-Reurink M.P., Drizdal T., et al. Reirradiation combined with hyperthermia in breast cancer recurrences: overview of experience in erasmus MC. Int. J. Hyperth. 2010, 26:638-648.
54. van der Zee J., Wijnmaalen A.J., Haveman J., Woudstra E., van der Ploeg S.K. Hyperthermia may decrease the development of telangiectasia after radiotherapy. Int. J. Hyperth. 1998, 14:57-64.
55. van der Zee J., van Rhoon G.C., Wike-Hooley J.L., Faithfull N.S., Reinhold H.S. Whole-body hyperthermia in cancer therapy: a report of a phase I-II study. Eur. J. Cancer Clin. Oncol. 1983, 19:1189-1200.